Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22323360 | 0.74 | SPR (0.36) | HSP90AA1ADORA2AADORA1NOS1ALDH1A1 | |
| SCHEMBL15391120 | 0.74 | HSP90AA1 (0.36) | HSP90AA1ADORA2AADORA1NOS1ALDH1A1 | |
| SCHEMBL368657 | 0.74 | CYP2A6 (0.42) | HSP90AA1ADORA2AADORA1ALDH1A1KDM4E | |
| SCHEMBL660369 | 0.74 | AXL (0.48) | HSP90AA1ADORA2AADORA1DYRK1ACYP2A6 | |
| SCHEMBL32691515 | 0.74 | SPR (0.36) | HSP90AA1ADORA2AADORA1NOS1ALDH1A1 | |
| SCHEMBL29377266 | 0.74 | AXL (0.48) | HSP90AA1ADORA2AADORA1DYRK1ACYP2A6 | |
| SCHEMBL20265450 | 0.74 | ADORA2A (0.33) | HSP90AA1ADORA2AADORA1NOS1ALDH1A1 | |
| SCHEMBL8016628 | 0.74 | PDE3B (0.39) | HSP90AA1ADORA2AADORA1ALDH1A1DYRK1A | |
| SCHEMBL29494911 | 0.71 | BRAF (0.38) | ADORA2AADORA1ALDH1A1LIMK1CYP2A6 | |
| SCHEMBL369046 | 0.71 | BRAF (0.38) | ADORA2AADORA1ALDH1A1LIMK1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | claimed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| WO-2014035829-A1 | SUBSTITUTED 3-AMINOTHIENO[2,3-C]PYRIDINE-2-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2013052394-A1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| US-6103736-A | SHOWING AN INHIBITORY ACTION ON GASTRIC ACID SECRETION AND A PROTECTIVE ACTION OF GASTRIC MUCOSA; 2-(HETERO)ARYL-3-AMINOIMIDAZO-(2,1-A)ISOQUINOLINES; ANTIULCER AGENTS; | SHINNIPPON PHARMACEUTICAL INC. (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| US-6020342-A | Fused imidazo[1,2-A]pyridines | SHINNIPPON PHARMACEUTICAL, INC. (JP) | 2000-02-01 | — | — | US | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| EP-0822194-A1 | FUSED IMIDAZO 1,2-a]PYRIDINES | Shinnippon Pharmaceutical Inc. (JP) | 1998-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | HSP90AA1 96/4885ADORA2A 2647/4885ADORA1 3577/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | HSP90AA1 2908/4885ADORA2A 254/4885ADORA1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.